In celebration of her upcoming PhD defence on 28 May, Voices in the Field interviewed Eva Zhang about her experience as a researcher specialising in the right to health in China. Zhang’s thesis, entitled ‘Advancing the Right to Health Care in China – Towards Accountability’ looked into accountability for the implementation of the right to health in China, and the various mechanisms such accountability might take. Zhang is also the Chinese liaison of the GHLG Research Centre, in which she establishes relationships between universities and research institutions in the Netherlands and China.
Join us at our conference Law and Noncommunicable Diseases: The crosscutting role of law in NCD control and regulating risk factors on 31 May and 1 June in Groningen.
By Professor Brigit Toebes, Academic Director, Global Health Law Groningen Research Centre
English: The sugar tax does not receive the attention it deserves in the Netherlands. Research indicates that a price increase of fizzy drinks in particular can reduce its consumption. It is time for a more concerted governmental, societal, and scientific debate in the Netherlands about the pros and cons of this measure.
Nederlands: de suikertaks krijgt niet de aandacht die hij verdient in Nederland. Onderzoek toont aan dat een prijsverhoging van met name frisdrank de consumptie ervan kan verlagen, hetgeen kan bijdragen aan het terugdringen van overgewicht.
By Dean M. Harris, J.D., Associate Professor, Department of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, USA, Dean_Harris@unc.edu
In January of 2017, I wrote a blog post for Global Health Law Groningen about the global health effects of the 2016 U.S. election. I wrote it a few days before the inauguration of a new president. At that time, I made some predictions about the likely effects of the election on the U.S. role in global health.
I wish that my predictions had been wrong. In fact, the actual results have been worse than anticipated. My predictions in January of 2017 were that “It is very likely that the change of government in the U.S. will: (1) reduce access to reproductive health services; (2) change the amounts and priorities of development aid from the U.S. government; (3) reduce progress in responding to global environmental problems; and (4) change U.S. immigration policies in ways that adversely affect other countries.” Specifically, I noted that the new president might reinstate the U.S. government’s Mexico City Policy, which critics call the “global gag rule.”
By Ellen ‘t Hoen, Global Health Unit Department of Health Sciences, UMCG Groningen, firstname.lastname@example.org.
This month the European Commission published Innovative Payment Models for High-Cost Innovative Medicines, a report of the Expert Panel on effective ways of investing in Health (EXPH).
The report examines new ways of paying for new and costly medicines as a means to finding solutions for the ever-increasing prices of new pharmaceutical treatments. The panel does not shy away from exploring hot-button topics such as the need for greater transparency in medicines pricing, R&D and marketing cost, enlisting competition authorities to investigate drug pricing, ‘orphanisation’ of new medicines, revisiting the patent and market exclusivity as a cornerstone of innovation, developing alternative paths for innovation financing based on delinkage principles such as prize awards and the question how to ensure a ‘public return on public investment’. It further explores ways to bolster negotiating power of governments in price negotiations, including through the use of compulsory licensing of medicines patents.
The European Scientific Network on Law and Tobacco (ESNLT) as led by the Global Health Law Groningen Research Centre of the University of Groningen, and the Leuven Institute for Healthcare Policy and the Leuven Centre for Public Law of the KU Leuven with support of the European Association of Health Law, cordially invite you to the conference:
Law and Noncommunicable Diseases:
The cross-cutting role of law in NCD control and regulating risk factors
31 May – 1 June 2018 in Groningen, The Netherlands
By Tatia M. Brunings, GHLG Research Volunteer, email@example.com
The World Health Organization (WHO) has been a constant advocate for the promotion of taxation on sugary beverages in order to combat the rise of non-communicabe diseases (NCDs). In January 2014, the Mexican government enacted a law with a taxation rate of 10%, an increase of one peso, on sugary beverages. At the time, 32.8% of the Mexican population was obese, and the country was considered to have the largest obesity rate in the world, according to the United Nation’s Food and Agricultural Organization. Studies show that Mexico’s sugar tax led to a continuous decrease in consumption seen within its first two years of implementation. This raises the question: To what extent would it be effective to implement taxation on sugary beverages as seen in Mexico in 2014, within the Netherlands?